Product
PG2
6 clinical trials
9 indications
Indication
Quality of LifeIndication
FatigueIndication
ComplementaryIndication
MetastasisIndication
Cancer RecurrenceIndication
Idiopathic Thrombocytopenic PurpuraIndication
CancerIndication
SurgeryIndication
Hemorrhagic StrokeClinical trial
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced MalignancyStatus: Completed, Estimated PCD: 2003-10-01
Clinical trial
The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)Status: Completed, Estimated PCD: 2011-08-01
Clinical trial
The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for CancerStatus: Withdrawn, Estimated PCD: 2020-12-01
Clinical trial
The Pilot Clinical Study of PG2 Injection on Hemorrhagic StrokeStatus: Completed, Estimated PCD: 2013-09-01
Clinical trial
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative CareStatus: Completed, Estimated PCD: 2008-01-01